Anders Kristensson appointed CEO of TikoMed
Viken – 18th June 2018
TikoMed, a privately-held biopharmaceutical company today announced the appointment of Anders Kristensson as their new Chief Executive Officer. He succeeds Adam Bruce founder and acting CEO, who will continue as Executive board member, building the IBsolvMIR® program.
TikoMed is developing therapeutics for treating acute and degenerative neurological and ophthalmic diseases (ILB program) and an infusion product for improving outcomes in cell therapies (IBsolvMIR program). The company is planning to initiate phase II studies in ALS (Amyotrophic Lateral Sclerosis) at Sahlgrenska University Hospital and Birmingham University Hospital in the second half of 2018. Other areas are Glaucoma, Alzheimer, Stroke and Traumatic brain injury.
“I’m delighted to welcome Anders Kristensson as Chief Executive Officer of TikoMed”, said Dr. Stefan Sallerfors, Chairman of TikoMed. “Anders experience from big pharma and his entrepreneurial background are tremendous assets, that will allow TikoMed to take next steps and prepare for an exit through a partnering deal or trade sale in the next 12-18 months.
“I am honored to join TikoMed at this time for the next phase of its exciting journey as we initiate our Phase II clinical programs”, said Anders Kristensson. “I believe TikoMed has a very valuable lead asset in ILB, that could become a game changer in the neurological space, but more importantly make a big difference for patients suffering from these devastating diseases.
Anders Kristensson joins TikoMed after serving as General Manager for Nordics and the Baltics at Eli Lilly and Company. He has extensive leadership experience in the life science industry, having built strong teams and commercial results in the Nordics, Europe and the Middle East. Anders holds a Master Diploma in Business and Administration from Lund University.